We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Swiss finish

18 April 2012 By Quentin Webb

The Swiss drugmaker is walking away after failing to cajole the gene-sequencing firm into talks. Shareholders clearly weren’t pushing Illumina to the table, and a wobble in its shares now won’t change that. But Roche could return if the stock continues to languish.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)